/
Oncology
Esophageal Squamous Cell Carcinoma
107
Pipeline Programs↗
130
Active Trials↗
49
Companies Involved↗
Esophageal Squamous Cell Carcinoma is a highly competitive landscape with 107 programs across 49 companies. The most active players are Merck & Co., CSPC Megalith Biopharmaceutical Co.,Ltd., Sichuan Baili Pharmaceutical Co., Ltd.. 24 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical22
Phase 15
Phase 256
Phase 324
Approved
No programs
Analysis
Modality Breakdown
77%
Small molecule
77 of 100 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 100 classified programs, each share of the total. Modality classified for 96% of 107 pipeline programs.
Analysis
Trial Status
250
clinical trials
Recruiting72 · 29%
Unknown status69 · 28%
Completed40 · 16%
Not yet recruiting38 · 15%
Active, not recruiting14 · 6%
Terminated8 · 3%
Other9 · 4%
Clinical Trials
Trial Activity
250 trials
Page 1 of 17
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)